Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy

Alberto Zambelli, Gian Antonio Da Prada, Vittorio Fregoni, Luisa Ponchio, Paola Sagrada, Lorenzo Pavesi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Although several antineoplastic agents have been proven to be safe for the fetus after the organogenesis period, there is limited information on their use during the first trimester of pregnancy. Herein we report the first case of a patient with metastatic lung cancer treated with erlotinib during the first 2 months of an unrecognized pregnancy. A 30-year-old woman was diagnosed with stage IV non-small cell lung cancer with bone and lung metastasis. The patient received 4 months of palliative cisplatin/gemcitabine chemotherapy and biphosphonates. After 12 months the disease progressed and the patient received erlotinib 100 mg/day. During this period the patient became pregnant. Since she recalled the date of her last menstrual period at about 15 days prior to the start of the therapy, we did consider the possibility of conception at the time of the first day of erlotinib administration. Informed about the risk for the fetus due to erlotinib, the patient stopped anticancer treatment. After 42 weeks of regular gestation, cesarean section was performed, delivering a 3490 g female new-born with no evidence of congenital malformations. The disease evaluation performed with thoracic CT scan, after 1 month from the childbirth, showed a progressive lung metastasis and erlotinib treatment was resumed at the dose of 150 mg/day.

Original languageEnglish
Pages (from-to)455-457
Number of pages3
JournalLung Cancer
Volume60
Issue number3
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Pregnancy
gemcitabine
Lung Neoplasms
Fetus
Neoplasm Metastasis
Bone Neoplasms
Organogenesis
First Pregnancy Trimester
Cesarean Section
Antineoplastic Agents
Cisplatin
Thorax
Therapeutics
Erlotinib Hydrochloride
Parturition
Drug Therapy
Lung

Keywords

  • Erlotinib
  • Lung cancer
  • Pregnancy

ASJC Scopus subject areas

  • Oncology

Cite this

Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. / Zambelli, Alberto; Prada, Gian Antonio Da; Fregoni, Vittorio; Ponchio, Luisa; Sagrada, Paola; Pavesi, Lorenzo.

In: Lung Cancer, Vol. 60, No. 3, 06.2008, p. 455-457.

Research output: Contribution to journalArticle

Zambelli, Alberto ; Prada, Gian Antonio Da ; Fregoni, Vittorio ; Ponchio, Luisa ; Sagrada, Paola ; Pavesi, Lorenzo. / Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. In: Lung Cancer. 2008 ; Vol. 60, No. 3. pp. 455-457.
@article{295ef452992f4cb7828f08e7aa3b4048,
title = "Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy",
abstract = "Although several antineoplastic agents have been proven to be safe for the fetus after the organogenesis period, there is limited information on their use during the first trimester of pregnancy. Herein we report the first case of a patient with metastatic lung cancer treated with erlotinib during the first 2 months of an unrecognized pregnancy. A 30-year-old woman was diagnosed with stage IV non-small cell lung cancer with bone and lung metastasis. The patient received 4 months of palliative cisplatin/gemcitabine chemotherapy and biphosphonates. After 12 months the disease progressed and the patient received erlotinib 100 mg/day. During this period the patient became pregnant. Since she recalled the date of her last menstrual period at about 15 days prior to the start of the therapy, we did consider the possibility of conception at the time of the first day of erlotinib administration. Informed about the risk for the fetus due to erlotinib, the patient stopped anticancer treatment. After 42 weeks of regular gestation, cesarean section was performed, delivering a 3490 g female new-born with no evidence of congenital malformations. The disease evaluation performed with thoracic CT scan, after 1 month from the childbirth, showed a progressive lung metastasis and erlotinib treatment was resumed at the dose of 150 mg/day.",
keywords = "Erlotinib, Lung cancer, Pregnancy",
author = "Alberto Zambelli and Prada, {Gian Antonio Da} and Vittorio Fregoni and Luisa Ponchio and Paola Sagrada and Lorenzo Pavesi",
year = "2008",
month = "6",
doi = "10.1016/j.lungcan.2007.10.025",
language = "English",
volume = "60",
pages = "455--457",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy

AU - Zambelli, Alberto

AU - Prada, Gian Antonio Da

AU - Fregoni, Vittorio

AU - Ponchio, Luisa

AU - Sagrada, Paola

AU - Pavesi, Lorenzo

PY - 2008/6

Y1 - 2008/6

N2 - Although several antineoplastic agents have been proven to be safe for the fetus after the organogenesis period, there is limited information on their use during the first trimester of pregnancy. Herein we report the first case of a patient with metastatic lung cancer treated with erlotinib during the first 2 months of an unrecognized pregnancy. A 30-year-old woman was diagnosed with stage IV non-small cell lung cancer with bone and lung metastasis. The patient received 4 months of palliative cisplatin/gemcitabine chemotherapy and biphosphonates. After 12 months the disease progressed and the patient received erlotinib 100 mg/day. During this period the patient became pregnant. Since she recalled the date of her last menstrual period at about 15 days prior to the start of the therapy, we did consider the possibility of conception at the time of the first day of erlotinib administration. Informed about the risk for the fetus due to erlotinib, the patient stopped anticancer treatment. After 42 weeks of regular gestation, cesarean section was performed, delivering a 3490 g female new-born with no evidence of congenital malformations. The disease evaluation performed with thoracic CT scan, after 1 month from the childbirth, showed a progressive lung metastasis and erlotinib treatment was resumed at the dose of 150 mg/day.

AB - Although several antineoplastic agents have been proven to be safe for the fetus after the organogenesis period, there is limited information on their use during the first trimester of pregnancy. Herein we report the first case of a patient with metastatic lung cancer treated with erlotinib during the first 2 months of an unrecognized pregnancy. A 30-year-old woman was diagnosed with stage IV non-small cell lung cancer with bone and lung metastasis. The patient received 4 months of palliative cisplatin/gemcitabine chemotherapy and biphosphonates. After 12 months the disease progressed and the patient received erlotinib 100 mg/day. During this period the patient became pregnant. Since she recalled the date of her last menstrual period at about 15 days prior to the start of the therapy, we did consider the possibility of conception at the time of the first day of erlotinib administration. Informed about the risk for the fetus due to erlotinib, the patient stopped anticancer treatment. After 42 weeks of regular gestation, cesarean section was performed, delivering a 3490 g female new-born with no evidence of congenital malformations. The disease evaluation performed with thoracic CT scan, after 1 month from the childbirth, showed a progressive lung metastasis and erlotinib treatment was resumed at the dose of 150 mg/day.

KW - Erlotinib

KW - Lung cancer

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=44249102125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249102125&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.10.025

DO - 10.1016/j.lungcan.2007.10.025

M3 - Article

C2 - 18063195

AN - SCOPUS:44249102125

VL - 60

SP - 455

EP - 457

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -